DEFA14A ·Filed Apr 3, 2026

NUS

NU SKIN ENTERPRISES, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001140361-26-013154
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for any shareholder activism or governance concerns given the recent executive changes. The vote on the amended omnibus incentive plan may indicate future compensation strategy.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
NUS ▼ -30.19% at T+60d
NEUTRAL call ✗ call lost -30.19% · α vs SPY -43.66% · entry $7.52 → $5.25
Entry anchored
Apr 2, 03:59 PM ET
via exchange tick
T+1d
-3.06%
call -3.06% · α -3.12%
$7.29
settled 6mo ago
T+5d
-0.13%
call -0.13% · α -4.27%
$7.51
settled 6mo ago
T+20d
-6.25%
call -6.25% · α -15.23%
$7.05
settled 5mo ago
T+60d
-30.19%
call -30.19% · α -43.66%
$5.25
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Nu Skin Enterprises is holding its annual shareholder meeting on May 28, 2026, where shareholders will vote on director elections, executive compensation, an amended omnibus incentive plan, and auditor ratification. This filing is routine, but follows recent executive changes including the CFO's resignation and a new COO appointment, suggesting potential board/executive transition activity.

Key Facts

  • Annual shareholder meeting scheduled for May 28, 2026
  • Shareholders will vote on 9 director nominees, executive compensation, an amended omnibus incentive plan, and auditor ratification
  • Board/executive changes occurred recently: CFO resigned on March 17, 2026 and interim CFO appointed; new COO appointed on March 5, 2026
  • PricewaterhouseCoopers LLP recommended for auditor ratification

Financial Impact

No direct financial impact from this filing

Risk Factors

  • Potential governance concerns due to recent executive turnover
  • Shareholder opposition to executive compensation or incentive plan

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-013154
Document: 0001140361-26-013154-index-headers.html0001140361-26-013154
Document: 0001140361-26-013154-index.html0001140361-26-013154
Document: 0001140361-26-013154.txt0001140361-26-013154
4 reports for NUS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NUS — sortable, filterable
TypeNow
Aug 10, 2026
7w ago
8-K
BEARISH ★ 7/10
$4.87 $4.85▲ +0.41%▼ −0.65%$4.61 (+5.34%)
Jun 12, 2026
16w ago
Institutional Cluster
BEARISH ★ 5/10
$5.47 $5.23▲ +4.39%▲ +6.17%$4.61 (+15.72%)
May 8, 2026
21w ago
8-K
NEUTRAL ★ 2/10
$6.63 $5.44▼ −17.95%▼ −17.64%$4.61 (−30.47%)
Apr 3, 2026
26w ago
DEFA14A
NEUTRAL ★ 3/10
$7.52 $7.05▼ −6.25%▼ −15.23%$4.61 (−38.70%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (34h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access